WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · HB 1669

Legislative bill overview

HB 1669 relates to lung cancer screening procedures and protocols in Hawaii, though the specific provisions are not detailed in the legislative record provided. The bill was introduced in January 2026 and is currently under review by the Health (HLT) and Consumer Protection (CPC) committees. It is scheduled for a hearing in February 2026.

Why is this important

Lung cancer screening can detect disease at earlier, more treatable stages, potentially improving survival rates and reducing healthcare costs. Policy changes around screening protocols affect accessibility, insurance coverage, and clinical standards across the state, impacting both individual health outcomes and public health resources.

Potential points of contention

  • Screening criteria and eligibility – Defining who qualifies for screening (age, smoking history, risk factors) affects program costs and reach; stricter criteria may exclude high-risk individuals while broader criteria increase expenses
  • Insurance coverage and cost responsibility – Whether screening is fully covered, partially subsidized, or patient-paid; cost-sharing debates often arise between insurers, providers, and patient advocates
  • Implementation standards – Establishing which facilities can perform screenings, equipment requirements, and provider qualifications may create compliance challenges for rural or underserved areas

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.